Skip to main content
. Author manuscript; available in PMC: 2019 Apr 4.
Published in final edited form as: Pharmacotherapy. 2018 Jul 26;38(9):907–920. doi: 10.1002/phar.2158

Figure 3.

Figure 3.

Quarterly trends in oral anticoagulant prescriptions for atrial fibrillation by age, from the fourth quarter of 2010 (2010Q4) to the first quarter of 2017 (2017Q1)

Y-axis refers to the percentage of incident OAC users prescribed a specific OAC.

OAC indicates oral anticoagulant; NOAC, non-vitamin K antagonist oral anticoagulant, including dabigatran, rivaroxaban, and apixaban.